GSK (LON:GSK) Insider Acquires £28,215 in Stock

Key Points

• GSK insider Jonathan Symonds purchased 1,500 shares at GBX 1,881 each, investing a total of £28,215.
• GSK shares edged down 0.1% to GBX 1,908.50, with the company valued at approximately £76.47 billion and trading between a one-year range of GBX 1,455 to GBX 2,282.
• Analysts maintain a consensus “Hold” rating with an average price target of GBX 2,064.38, while GSK recently reported quarterly EPS of GBX 10.80.

GSK plc (LON:GSK - Get Free Report) insider Jonathan Symonds purchased 1,500 shares of GSK stock in a transaction dated Friday, September 18th. The stock was bought at an average cost of GBX 1,881 per share, for a total transaction of £28,215.

GSK Stock Down 0.1%

Shares of GSK stock traded down GBX 2.50 during trading on Tuesday, reaching GBX 1,908.50. The company's stock had a trading volume of 1,767,880,500 shares, compared to its average volume of 22,712,896. GSK plc has a 1-year low of GBX 1,455 and a 1-year high of GBX 2,282. The stock's 50-day moving average price is GBX 1,890.22 and its 200 day moving average price is GBX 1,953.51. The company has a market capitalization of £76.47 billion, a price-to-earnings ratio of 16.20, a P/E/G ratio of 1.24 and a beta of 0.29. The company has a debt-to-equity ratio of 103.36, a current ratio of 0.82 and a quick ratio of 0.73.

GSK (LON:GSK - Get Free Report) last issued its quarterly earnings results on Tuesday, July 28th. The company reported GBX 10.80 EPS for the quarter. GSK had a net margin of 14.52% and a return on equity of 28.35%. On average, research analysts anticipate that GSK plc will post 175.980975 EPS for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Berenberg Bank increased their target price on GSK from GBX 2,000 to GBX 2,200 and gave the company a "hold" rating in a report on Tuesday, September 15th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and issued a GBX 2,000 target price on shares of GSK in a research report on Tuesday, September 15th. Jefferies Financial Group reiterated a "buy" rating and set a GBX 2,500 price target on shares of GSK in a research note on Wednesday, July 29th. Finally, Royal Bank Of Canada reissued a "sector perform" rating and issued a GBX 1,975 price target on shares of GSK in a research report on Tuesday, September 8th. Two research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of GBX 2,064.38.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.